Inve India ▾

Laurus Labs share price & results

Laurus Labs· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Integrated API, formulation and CDMO manufacturer serving global pharma, biotech and animal-health customers.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue1,757 ₹ crore+22.6% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin28.0 %+5.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit290 ₹ crore+83.5% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity22.37 %+11.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin8.23 %+7.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)22.60 %+12.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 of 6 judged targets kept · 17 open · verdicts reflect calls analysed to Q1 FY27.

Laurus Labs management guidance track record on Inve: 23 targets tracked across analysed earnings calls (5 achieved, 1 missed, 17 open).

TargetOriginal wordingSaidLatest callVerdict
ARV Sales FY26INR 2,400-2,600 crores
Call transcript, Q4 FY25 · 24 Apr 2025		Q4 FY25Q1 FY27:Promise achieved in FY26. No new updates.
Call transcript, Q1 FY27 · 24 Jul 2026		Achieved
ImmunoACT NexCAR19 Capacityready for operations by September 25
Call transcript, Q4 FY25 · 24 Apr 2025		Q4 FY25Q1 FY27:No update provided on the missed September 2025 deadline. The topic remains unaddressed.
Call transcript, Q1 FY27 · 24 Jul 2026		Ghosted
2-Year Capex Plan (FY27-FY28)around INR 3,000 crores in the next 2 years
Call transcript, Q4 FY26 · 30 Apr 2026		Q4 FY26Q1 FY27:Management indicated the INR 3,000 crore plan for FY27-28 might be exceeded: 'We may do more than that'. This signals a potential upward revision.
Call transcript, Q1 FY27 · 24 Jul 2026		Revised Up

Source: Inve Guidance Tracker for Laurus Labs · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Laurus Labs's 23 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 20 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,058.9 +4.51% · +₹88.9

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +122.2% 1Y

₹1.0k₹1.5k₹2.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 24 Oct 2025Q3 FY26 — 23 Jan 2026Q3 FY26 — 28 Jan 2026Q4 FY26 — 30 Apr 2026Q1 FY27 — 24 Jul 2026

1Y: ₹926.4 on 24 Oct 2025 → ₹2,058.9. High ₹2,069.2 (12 Oct 2026), low ₹926.4 (24 Oct 2025).

Previous close
₹1,970
Market cap
₹1.2L Cr
52-week range
₹930.2 – ₹2,069.2
One year
+119.00%
Price to earnings (TTM to Jun 2026)
105.83×
Return on equity (TTM to Jun 2026)
22.37%

Overview

Symbol
NSE:LAURUSLABS
Exchange
NSE
Currency
INR

What Laurus Labs does

Based on the company's own presentations, annual report and earnings calls.

Laurus Labs is a research-led pharmaceutical and biotechnology manufacturer operating across two business divisions: Contract Development & Manufacturing (CDMO) for global pharma, biotech, animal-health and crop-science customers, and Affordable Medicines (generic APIs and finished-dosage formulations), historically anchored in antiretroviral (ARV) drugs and now expanding into oncology, cardiovascular, diabetes, gastro and asthma. It earns by manufacturing and supplying active pharmaceutical ingredients (APIs) and finished dosage forms (FDF) to institutional, generic and innovator pharma customers, and by providing contract development and manufacturing services (including small-molecule, biocatalysis and emerging-modality process work) to global pharma and biotech partners. The company is also building capability in fermentation-based biologics, peptides, cell and gene therapy (including an ADC/gene-therapy process-development lab) alongside its core small-molecule chemistry business.

Segments

  • CDMO (Contract Development & Manufacturing)
  • Affordable Medicines (Generics)
Manufacturing sites
15 (7 approved for developed markets incl. US FDA)
Installed API/CDMO reactor volume
~8,200 KL
Formulation (oral dosage) capacity
12 billion units/annum
Fermentation capacity
240 KL
API product portfolio (cumulative DMF filings)
92
FDF product portfolio
94
Employees 8,126 (FY26 (as of March 31, 20) Company website

How the price took the results

close before → close after

Q1 FY27
+2.1%
24 Jul
Q4 FY26
−0.5%
30 Apr
Q3 FY26
+1.1%
23 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Laurus Labs

Free account: one company. Everything above stays public.

Write why you follow Laurus Labs and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Laurus Labs

Guides on how to read this kind of business and the numbers that matter.